medigraphic.com

2008, Number 4

<< Back Next >>

Med Sur 2008; 15 (4)

Advanced renal cancer: Currents in the medical treatment

Green RD, Sosa SR

Language: Spanish
References: 82
Page: 278-287
PDF size: 139.24 Kb.


ABSTRACT

Renal cell carcinoma (RCC) is the most common form of kidney cancer. RCC is associated to altered function in the Von Hippel-Lindau gene and altered activation of the hypoxia induced factor. In the majority of cases the presence of symptomatic disease is equivalent to advanced disease. RCC is a curable disease at early stages with surgery. Treatment of advanced or metastatic RCC is difficult because of a poor response to conventional chemotherapy agents. With the advent of new treatment modalities like immunotherapy and molecular targeted therapies, better responses and longer survival have been demonstrated. This review resumes the novel therapeutics and current treatment of advanced RCC.


REFERENCES

  1. Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J Clin 2006; 56: 106-30.

  2. JR, Lerman MI, Zbar B et al. Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 1995; 22: 3-8.

  3. Kondo K, Yao M, Yoshida M et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002; 34: 58-68.

  4. Gallou C, Joly D, Mejean A et al. Mutations of the VHL gene in sporadic renal cell carcinoma: Definition of a risk factor for VHL patients to develop an RCC. Hum Mutat 1999; 13: 464-75.

  5. Schraml P, Struckmann K, Hatz F et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002; 196: 186-93.

  6. Clifford SC, Prowse AH, Affara NA et al. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 1998; 22: 200-9.

  7. Herman JG, Latif F, Weng Y et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994; 91: 9700-4.

  8. Kibel A, Iliopoulos O, DeCaprio JA et al. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 1995; 269: 1444-6.

  9. Kaelin WG Jr. The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem Biophys Res Commun 2005; 338: 627-38.

  10. Soccio RE, Adams RM, Maxwell KN et al. Differential gene regulation of StarD4 and StarD5 cholesterol transfer proteins. Activation of StarD4 by sterol regulatory element-binding protein-2 and StarD5 by endoplasmic reticulum stress. J Biol Chem 2005; 280: 19410-8.

  11. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22: 4991-5004.

  12. Kourembanas S, Hannan RL, Faller DV. Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells. J Clin Invest 1990; 86: 670-4.

  13. Maldazys JD, deKernion JB. Prognostic factors in metastatic renal carcinoma. J Urol 1986; 136: 376-9.

  14. Guinan P, Sobin LH, Algaba F et al. TNM staging of renal cell carcinoma: Workgroup No. 3 Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997; 80: 992.

  15. Walther MM, Patel B, Choyke PL et al. Hypercalcemia in patients with metastatic renal cell carcinoma: effect of nephrectomy and metabolic evaluation. J Urol 1997; 158: 733-9.

  16. Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol 1989; 63: 128-31.

  17. Montie JE, Stewart BH, Straffon RA et al. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 1977; 117: 272-5.

  18. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655-9.

  19. Mickisch GH, Garin A, van Poppel H et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomized trial. Lancet 2001; 358: 966-70.

  20. Flanigan RC, Mickisch G, Sylvester R et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004; 171: 1071-6.

  21. Hemstreet GP 3rd, Wittliff JL, Sarrif AM et al. Comparison of steroid receptor levels in renal-cell carcinoma and autologous normal kidney. Int J Cancer 1980; 26: 769-75.

  22. Pearson J, Friedman MA, Hoffman PG Jr. Hormone receptors in renal cell carcinoma. Their utility as predictors of response to endocrine therapy. Cancer Chemother Pharmacol 1981; 6: 151-4.

  23. Kirkman H, Bacon RL. Estrogen-induced tumors of the kidney. I. Incidence of renal tumors in intact and gonadectomized male golden hamsters treated with diethylstilbestrol. J Natl Cancer Inst 1952; 13: 745-55.

  24. Hamilton JM, Flaks A, Saluja PG, et al. Hormonally induced renal neoplasia in the male Syrian hamster and the inhibitory effect of 2-bromo-alpha-ergocryptine methanesulfonate. J Natl Cancer Inst 1975; 54(6): 1385-400.

  25. Kjaer M. The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma. Cancer Treat Rev 1988; 15: 195-209.

  26. Weiselberg L, Budman D, Vinciguerra V et al. Tamoxifen in unresectable hypernephroma. A phase II trial and review of the literature. Cancer Clin Trials 1981; 4(2): 195-8.

  27. Oh WK, Manola J, George DJ et al. A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients. Cancer Invest 2002; 20(2): 186-91.

  28. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993; 20: 303-21.

  29. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995; 22: 42-60.

  30. Motzer RJ, Murphy BA, Bacik J et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 2972-80.

  31. Stadler WM, Halabi S, Rini B et al. Cancer and leukemia group B. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer 2006; 107: 1273-9.

  32. Waters JS, Moss C, Pyle L, James M, Hackett S, A’hern R et al. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br J Cancer 2004; 91: 1763-1768.

  33. Neidhart JA, Anderson SA, Harris JE et al. Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. J Clin Oncol 1991; 9: 832-6.

  34. Thomas H, Barton C, Saini A et al. Sequential interleukin-2 and alpha interferon for renal cell carcinoma and melanoma. Eur J Cancer 1992; 28A(6-7): 1047-9.

  35. Motzer RJ, Lyn P, Fischer P et al. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 1995; 13: 1958-65.

  36. Warner E, Tobe SW, Andrulis IL et al. Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell arcinoma. Am J Clin Oncol 1995; 18: 251-6.

  37. Snow RM, Schellhammer PF. Spontaneous regression of metastatic renal cell carcinoma. Urology 1982; 20: 177-81.

  38. Costa LJ, Drabkin HA. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 2007; 12: 1404-15.

  39. Fyfe GA, Fisher RI, Rosenberg SA et al. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996; 14: 2410-11.

  40. Fisher RI, Rosenberg SA, Sznol M et al. High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am 1997; 3: S70-72.

  41. Rosenberg SA, Yang JC, White DE et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998; 228: 307-19.

  42. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21: 3127-32.

  43. McDermott DF, Regan MM, Clark JI et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 133-141.

  44. Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9: 802-11.

  45. Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11: 3714-21.

  46. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet 1999; 353: 14-7.

  47. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-8.

  48. Eisen T, Boshoff C, Mak I et al. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000; 82: 812-817.

  49. Stebbing J, Benson C, Eisen T et al. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 2001; 85: 953-958.

  50. Minor DR, Monroe D, Damico LA et al. A phase II study of thalidomide in advanced metastatic renal cell carcinoma. Invest New Drugs 2002; 20: 389-93.

  51. Lee CP, Patel PM, Selby PJ et al. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 20: 898-903.

  52. Gordon MS, Manola J, Fairclough D et al. Low dose interferon-2b (IFN) + thalidomide (T) in patients with previously untreated renal cell cancer. Improvement in progression-free survival (PFS) but not quality of life or overall survival (OS). A phase III study of the Eastern Cooperative Oncology Group (E2898). Proc Am Soc Clin Oncol 2004; abstract 4516.

  53. Rawat A, Needle N, Miles B et al. Phase II study of CC-5013 in patients with metastatic renal cell cancer (MRCC). Proc Am Soc Clin Oncol 2005; abstract 4604.

  54. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005; 23: 1028-43.

  55. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-34.

  56. Bukowski RM, Kabbinavar FF, Figlin RA et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007; 25: 4536-41.

  57. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomized, double-blind phase III trial. Lancet 2007; 370: 2103-2111.

  58. Rini BI, Halabi S, Rosenberg JE et al. CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. Genitourinary Cancers Symposium, San Francisco, Feb 14-16, 2008. Abstract 350.

  59. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-37.

  60. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24.

  61. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24.

  62. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-109.

  63. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-12.

  64. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.

  65. Manning G, Whyte DB, Martinez R et al. The protein kinase complement of the human genome. Science 2002; 298: 1912-34.

  66. Hutson TE, Davis ID, Machiels JP et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT) (abstract 5031). J Clin Oncol 2007; 25(18S): 242s.

  67. Rixe O, Bukowski RM, Michaelson MD et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: A phase II study. Lancet Oncol 2007; 8: 975-84.

  68. Rini BI, Wilding GT, Hudes G et al. Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib (abstract 5032). J Clin Oncol 2007; 25(18S): 242s.

  69. Stephenson J, Schreeder M, Waples J et al. Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI) (abstract 15622). J Clin Oncol 207; 25(18S): 659s.

  70. Oliner J, Min H, Leal J et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004; 6: 507-16.

  71. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.

  72. Li Y, Corradetti MN, Inoki K, Guan KL. TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem Sci 2004; 29: 32-8.

  73. Figlin RA, Seligson D, Wu H. Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway. Proc Am Soc Clin Oncol 2005: abstract 4539.

  74. Kondo K, Yao M, Kobayashi K et al. PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. Int J Cancer 2001; 91: 219-24.

  75. Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-18.

  76. Escudier B, Eisen T, Stadler WM et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34.

  77. Amato RJ, Misellati A, Khan M et al. A phase II trial of RAD001 in patients with metastatic renal cell carcinoma (abstract 4530). J Clin Oncol 2006; 24(18S): 224s.

  78. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 2001; 61: 5090-101.

  79. New hope for RCC patients. Eur J Cancer 2006; 42: 1693.

  80. Jermann M, Joerger M, Pless M. An open-label phase II trial to evaluate the efficacy and safety of gefitinib in patients with locally advanced, relapsed or metastatic renal cell cancer. Proc Am Soc Clin Oncol 2003; 22: 418 (abstract 1681).

  81. Drucker BJ, Schwartz L, Marion S. Phase II trial of ZD1839 (Iressa), an EGF receptor inhibitor, in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 2002; 21: 181a (abstract 720).

  82. Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22: 3003-15.




2020     |     www.medigraphic.com